Sarepta Therapeutics (SRPT) PT Raised to $95.00
Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by investment analysts at JPMorgan Chase & Co. from $75.00 to $95.00 in a report released on Wednesday. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.’s price target would suggest a potential upside of 15.07% from the stock’s current price.
Several other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 5th. HC Wainwright initiated coverage on shares of Sarepta Therapeutics in a report on Friday, December 1st. They issued a “buy” rating and a $75.00 target price on the stock. BidaskClub raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Royal Bank of Canada initiated coverage on shares of Sarepta Therapeutics in a report on Monday, January 22nd. They issued an “outperform” rating on the stock. Finally, UBS Group reissued an “outperform” rating and issued a $56.51 target price (down from $76.00) on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $73.12.
Sarepta Therapeutics (NASDAQ SRPT) traded up $1.66 during trading hours on Wednesday, reaching $82.56. 298,789 shares of the company were exchanged, compared to its average volume of 1,681,275. Sarepta Therapeutics has a 1-year low of $28.14 and a 1-year high of $83.30. The company has a market capitalization of $5,230.00, a price-to-earnings ratio of -103.20 and a beta of 1.51. The company has a current ratio of 13.91, a quick ratio of 12.96 and a debt-to-equity ratio of 0.54.
Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Carillon Tower Advisers Inc. acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $38,720,000. Alyeska Investment Group L.P. acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at approximately $26,011,000. TimesSquare Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at approximately $21,521,000. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Sarepta Therapeutics by 63.4% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock valued at $48,564,000 after purchasing an additional 338,737 shares in the last quarter. Finally, Element Capital Management LLC acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at approximately $17,706,000. Institutional investors own 85.14% of the company’s stock.
WARNING: This piece of content was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/03/14/sarepta-therapeutics-srpt-pt-raised-to-95-00.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.